Abstract
With the advances in genomics, molecular biology including gene vector technologies todays molecular imaging modalities have strongly been improved. The major progress is based on peptide and antibody targeting vectors. When labeled with β-emitting radioisotopes these agents are applicable for endoradiotherapy and exploit the targeting potential for highly specific therapeutic applications. This novel class of pharmaceuticals offers the potential to develop patient specific therapies and might provide the means to go beyond the possibilities of current chemotherapy and radiation therapy. In this review the basic principles of endoradiotherapeutics based on peptides and proteins are presented. Several of these drugs such as 90Y-rituximab (Zevalin), 131I-tositumomab (Bexxar) and the somatostatin receptor binding 90YDOTATOC that are nowadays successfully applied in oncological therapy are discussed. Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries.
Keywords: Endoradiotherapy, oncology, labeling, radioisotopes, targeting
Protein & Peptide Letters
Title: Radiolabeled Peptides and Proteins in Cancer Therapy
Volume: 14 Issue: 3
Author(s): Carmen Wangler, Inga Buchmann, Michael Eisenhut, Uwe Haberkorn and Walter Mier
Affiliation:
Keywords: Endoradiotherapy, oncology, labeling, radioisotopes, targeting
Abstract: With the advances in genomics, molecular biology including gene vector technologies todays molecular imaging modalities have strongly been improved. The major progress is based on peptide and antibody targeting vectors. When labeled with β-emitting radioisotopes these agents are applicable for endoradiotherapy and exploit the targeting potential for highly specific therapeutic applications. This novel class of pharmaceuticals offers the potential to develop patient specific therapies and might provide the means to go beyond the possibilities of current chemotherapy and radiation therapy. In this review the basic principles of endoradiotherapeutics based on peptides and proteins are presented. Several of these drugs such as 90Y-rituximab (Zevalin), 131I-tositumomab (Bexxar) and the somatostatin receptor binding 90YDOTATOC that are nowadays successfully applied in oncological therapy are discussed. Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries.
Export Options
About this article
Cite this article as:
Wangler Carmen, Buchmann Inga, Eisenhut Michael, Haberkorn Uwe and Mier Walter, Radiolabeled Peptides and Proteins in Cancer Therapy, Protein & Peptide Letters 2007; 14 (3) . https://dx.doi.org/10.2174/092986607780090874
DOI https://dx.doi.org/10.2174/092986607780090874 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry Editorial Review of 2014
Current Radiopharmaceuticals Screening of Drug Efficacy of Rosmarinic Acid Derivatives as Aurora Kinase Inhibitors by Computer-Aided Drug Design Method
Current Computer-Aided Drug Design Immunonutrition in Surgical Patients
Current Drug Targets FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Current Medicinal Chemistry Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Novel 5-Methyl-2,4-Disubstitued-Oxazole Derivatives: Synthesis and Anticancer Activity
Letters in Drug Design & Discovery Novel 2-Thienyl- and 2-Benzothienyl-Substituted 6-(2-Imidazolinyl)Benzothiazoles: Synthesis; in vitro Evaluation of Antitumor Effects and Assessment of Mitochondrial Toxicity
Anti-Cancer Agents in Medicinal Chemistry Isothiocyanates in the Chemoprevention of Bladder Cancer
Current Drug Metabolism Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Adenovirus/PSA (Ad5-PSA) Vaccination for Prostate Cancer: Pre-Clinical and Clinical Development
Current Cancer Therapy Reviews Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery Synergistic Interplay of Medicinal Chemistry and Formulation Strategies in Nanotechnology – From Drug Discovery to Nanocarrier Design and Development
Current Topics in Medicinal Chemistry The Potency of Refined Mouse Models: Implications for Clinical Trials
Current Cancer Therapy Reviews